| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| - - | HOLD | 0 @ USD 0 | USD 0 | The current share valuation price of - based on adjusted close was USD 0. The average price that - shares were previous bought at was USD 0.00279608. The current market price is -100.0% lower than average price they were purchased at. USD 0 compared to the previous valuation of however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| 007390.KQ - NatureCell Co.,Ltd. | HOLD | 0 @ KRW 18.9591 | KRW 0 | The current share valuation price of 007390.KQ based on adjusted close was KRW 18.9591. The average price that 007390.KQ shares were previous bought at was KRW 21.5605. The current market price is -12.1% lower than average price they were purchased at. The value of the holding in 007390.KQ has increased by KRW 14,507 (USD $10) compared to the previous valuation of NatureCell Co.,Ltd. however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| 039200.KQ - Oscotec Inc. | HOLD | 0 @ KRW 36.8212 | KRW 0 | The current share valuation price of 039200.KQ based on adjusted close was KRW 36.8212. The average price that 039200.KQ shares were previous bought at was KRW 20.0221. The current market price is 83.9% higher than average price they were purchased at. The value of the holding in 039200.KQ has increased by KRW 35,085 (USD $24) compared to the previous valuation of Oscotec Inc. however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| 068270.KS - CELLTRION INC | HOLD | 0 @ KRW 130.211 | KRW 0 | The current share valuation price of 068270.KS based on adjusted close was KRW 130.211. The average price that 068270.KS shares were previous bought at was KRW 121.344. The current market price is 7.3% higher than average price they were purchased at. The value of the holding in 068270.KS has fallen by KRW 543,506 (USD $376) compared to the previous valuation of CELLTRION INC |
| 096530.KQ - Seegene, Inc. | HOLD | 0 @ KRW 18.0677 | KRW 0 | The current share valuation price of 096530.KQ based on adjusted close was KRW 18.0677. The average price that 096530.KQ shares were previous bought at was KRW 17.6796. The current market price is 2.2% higher than average price they were purchased at. The value of the holding in 096530.KQ has increased by KRW 22,060 (USD $15) compared to the previous valuation of Seegene, Inc. however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| 13.HK - HUTCHMED (CHINA) LTD | HOLD | 0 @ HKD 2.99742 | HKD 0 | The current share valuation price of 13.HK based on adjusted close was HKD 2.99742. The average price that 13.HK shares were previous bought at was HKD 3.03049. The current market price is -1.1% lower than average price they were purchased at. The value of the holding in 13.HK has fallen by HKD 40,483 (USD $5,209) compared to the previous valuation of HUTCHMED (CHINA) LTD |
| 182400.KQ - NKMAX LTD | HOLD | 0 @ KRW 4.27644 | KRW 0 | |
| 1877.HK - SHANGHAI JUNSHI BIOSCIENCES LTD H | HOLD | 0 @ HKD 3.18267 | HKD 0 | The current share valuation price of 1877.HK based on adjusted close was HKD 3.18267. The average price that 1877.HK shares were previous bought at was HKD 2.20212. The current market price is 44.5% higher than average price they were purchased at. The value of the holding in 1877.HK has fallen by HKD 26,855 (USD $3,456) compared to the previous valuation of SHANGHAI JUNSHI BIOSCIENCES LTD H |
| 207940.KS - SAMSUNG BIOLOGICS LTD | HOLD | 0 @ KRW 837.219 | KRW 0 | The current share valuation price of 207940.KS based on adjusted close was KRW 837.219. The average price that 207940.KS shares were previous bought at was KRW 720.393. The current market price is 16.2% higher than average price they were purchased at. The value of the holding in 207940.KS has fallen by KRW 11,860 (USD $8) compared to the previous valuation of SAMSUNG BIOLOGICS LTD |
| 2162.HK - KEYMED BIOSCIENCES INC | HOLD | 0 @ HKD 7.75084 | HKD 0 | The current share valuation price of 2162.HK based on adjusted close was HKD 7.75084. The average price that 2162.HK shares were previous bought at was HKD 5.23181. The current market price is 48.1% higher than average price they were purchased at. The value of the holding in 2162.HK has fallen by HKD 7,523 (USD $968) compared to the previous valuation of KEYMED BIOSCIENCES INC |
| 2252.HK - SHANGHAI MICROPORT MEDBOT CLASS H | HOLD | 0 @ HKD 2.93053 | HKD 0 | The current share valuation price of 2252.HK based on adjusted close was HKD 2.93053. The average price that 2252.HK shares were previous bought at was HKD 3.78461. The current market price is -22.6% lower than average price they were purchased at. The value of the holding in 2252.HK has fallen by HKD 45,411 (USD $5,843) compared to the previous valuation of SHANGHAI MICROPORT MEDBOT CLASS H |
| 237690.KQ - ST Pharm Co.,Ltd. | HOLD | 0 @ KRW 70.8997 | KRW 0 | The current share valuation price of 237690.KQ based on adjusted close was KRW 70.8997. The average price that 237690.KQ shares were previous bought at was KRW 54.2929. The current market price is 30.6% higher than average price they were purchased at. The value of the holding in 237690.KQ has fallen by KRW 7,996 (USD $6) compared to the previous valuation of ST Pharm Co.,Ltd. |
| 298380.KQ - ABL Bio Inc. | HOLD | 0 @ KRW 120.68 | KRW 0 | The current share valuation price of 298380.KQ based on adjusted close was KRW 120.68. The average price that 298380.KQ shares were previous bought at was KRW 40.1877. The current market price is 200.3% higher than average price they were purchased at. The value of the holding in 298380.KQ has increased by KRW 49,330 (USD $34) compared to the previous valuation of ABL Bio Inc. however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| 302440.KS - SK BIOSCIENCE LTD | HOLD | 0 @ KRW 37.4383 | KRW 0 | The current share valuation price of 302440.KS based on adjusted close was KRW 37.4383. The average price that 302440.KS shares were previous bought at was KRW 36.225. The current market price is 3.3% higher than average price they were purchased at. The value of the holding in 302440.KS has fallen by KRW 855 (USD $1) compared to the previous valuation of SK BIOSCIENCE LTD |
| 326030.KS - SK BIOPHARMACEUTICALS LTD | HOLD | 0 @ KRW 89.3445 | KRW 0 | The current share valuation price of 326030.KS based on adjusted close was KRW 89.3445. The average price that 326030.KS shares were previous bought at was KRW 73.1926. The current market price is 22.1% higher than average price they were purchased at. The value of the holding in 326030.KS has increased by KRW 44,922 (USD $31) compared to the previous valuation of SK BIOPHARMACEUTICALS LTD however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| 328130.KQ - Lunit Inc. | HOLD | 0 @ KRW 26.3645 | KRW 0 | The current share valuation price of 328130.KQ based on adjusted close was KRW 26.3645. The average price that 328130.KQ shares were previous bought at was KRW 36.9599. The current market price is -28.7% lower than average price they were purchased at. The value of the holding in 328130.KQ has increased by KRW 6,094 (USD $4) compared to the previous valuation of Lunit Inc. however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| 3933.HK - THE UNITED LABORATORIES INTERNATIO | HOLD | 0 @ HKD 1.5566 | HKD 0 | The current share valuation price of 3933.HK based on adjusted close was HKD 1.5566. The average price that 3933.HK shares were previous bought at was HKD 1.74455. The current market price is -10.8% lower than average price they were purchased at. The value of the holding in 3933.HK has fallen by HKD 119,651 (USD $15,396) compared to the previous valuation of THE UNITED LABORATORIES INTERNATIO |
| 4523.T - Eisai Co., Ltd. | HOLD | 0 @ JPY 30.1234 | JPY 0 | The current share valuation price of 4523.T based on adjusted close was JPY 30.1234. The average price that 4523.T shares were previous bought at was JPY 28.0807. The current market price is 7.3% higher than average price they were purchased at. The value of the holding in 4523.T has increased by JPY 116,717 (USD $755) compared to the previous valuation of Eisai Co., Ltd. however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| 4549.T - Eiken Chemical Co., Ltd. | HOLD | 0 @ JPY 15.2904 | JPY 0 | The current share valuation price of 4549.T based on adjusted close was JPY 15.2904. The average price that 4549.T shares were previous bought at was JPY 13.6521. The current market price is 12.0% higher than average price they were purchased at. The value of the holding in 4549.T has increased by JPY 2,137 (USD $14) compared to the previous valuation of Eiken Chemical Co., Ltd. however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| 4587.T - PeptiDream Inc. | HOLD | 0 @ JPY 10.2033 | JPY 0 | The current share valuation price of 4587.T based on adjusted close was JPY 10.2033. The average price that 4587.T shares were previous bought at was JPY 11.461. The current market price is -11.0% lower than average price they were purchased at. The value of the holding in 4587.T has fallen by JPY 45,653 (USD $295) compared to the previous valuation of PeptiDream Inc. |
| 4887.T - Sawai Group Holdings Co., Ltd. | HOLD | 0 @ JPY 12.1299 | JPY 0 | The current share valuation price of 4887.T based on adjusted close was JPY 12.1299. The average price that 4887.T shares were previous bought at was JPY 13.3982. The current market price is -9.5% lower than average price they were purchased at. The value of the holding in 4887.T has increased by JPY 21,515 (USD $139) compared to the previous valuation of Sawai Group Holdings Co., Ltd. however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| 4974.T - Takara Bio Inc. | HOLD | 0 @ JPY 5.28367 | JPY 0 | The current share valuation price of 4974.T based on adjusted close was JPY 5.28367. The average price that 4974.T shares were previous bought at was JPY 5.90785. The current market price is -10.6% lower than average price they were purchased at. The value of the holding in 4974.T has fallen by JPY 2,283 (USD $15) compared to the previous valuation of Takara Bio Inc. |
| 6869.T - Sysmex Corporation | HOLD | 0 @ JPY 9.85857 | JPY 0 | The current share valuation price of 6869.T based on adjusted close was JPY 9.85857. The average price that 6869.T shares were previous bought at was JPY 17.8798. The current market price is -44.9% lower than average price they were purchased at. The value of the holding in 6869.T has fallen by JPY 173,213 (USD $1,121) compared to the previous valuation of Sysmex Corporation |
| 6951.T - JEOL Ltd. | HOLD | 0 @ JPY 30.0461 | JPY 0 | The current share valuation price of 6951.T based on adjusted close was JPY 30.0461. The average price that 6951.T shares were previous bought at was JPY 33.4997. The current market price is -10.3% lower than average price they were purchased at. The value of the holding in 6951.T has fallen by JPY 202,607 (USD $1,311) compared to the previous valuation of JEOL Ltd. |
| 7575.T - Japan Lifeline Co., Ltd. | HOLD | 0 @ JPY 9.4784 | JPY 0 | The current share valuation price of 7575.T based on adjusted close was JPY 9.4784. The average price that 7575.T shares were previous bought at was JPY 10.3645. The current market price is -8.5% lower than average price they were purchased at. The value of the holding in 7575.T has increased by JPY 362 (USD $2) compared to the previous valuation of Japan Lifeline Co., Ltd. however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| 7701.T - Shimadzu Corporation | HOLD | 0 @ JPY 28.0164 | JPY 0 | The current share valuation price of 7701.T based on adjusted close was JPY 28.0164. The average price that 7701.T shares were previous bought at was JPY 25.4348. The current market price is 10.1% higher than average price they were purchased at. The value of the holding in 7701.T has fallen by JPY 169,000 (USD $1,093) compared to the previous valuation of Shimadzu Corporation |
| 7747.T - Asahi Intecc Co., Ltd. | HOLD | 0 @ JPY 17.2686 | JPY 0 | The current share valuation price of 7747.T based on adjusted close was JPY 17.2686. The average price that 7747.T shares were previous bought at was JPY 16.4838. The current market price is 4.8% higher than average price they were purchased at. The value of the holding in 7747.T has increased by JPY 530,953 (USD $3,435) compared to the previous valuation of Asahi Intecc Co., Ltd. however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| 9995.HK - REMEGEN LTD H | HOLD | 0 @ HKD 10.8898 | HKD 0 | The current share valuation price of 9995.HK based on adjusted close was HKD 10.8898. The average price that 9995.HK shares were previous bought at was HKD 9.31045. The current market price is 17.0% higher than average price they were purchased at. The value of the holding in 9995.HK has fallen by HKD 21,489 (USD $2,765) compared to the previous valuation of REMEGEN LTD H |
| A - Agilent Technologies Inc | HOLD | 0 @ USD 144.52 | USD 0 | The current share valuation price of A based on adjusted close was USD 144.52. The average price that A shares were previous bought at was USD 118.65. The current market price is 21.8% higher than average price they were purchased at. The value of the holding in A has fallen by USD 283,438 compared to the previous valuation of Agilent Technologies Inc |
| ABBV - AbbVie Inc | HOLD | 0 @ USD 234 | USD 0 | The current share valuation price of ABBV based on adjusted close was USD 234. The average price that ABBV shares were previous bought at was USD 191.211. The current market price is 22.4% higher than average price they were purchased at. The value of the holding in ABBV has increased by USD 128,527 compared to the previous valuation of AbbVie Inc however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| ABCL - Abcellera Biologics Inc | HOLD | 0 @ USD 3.6 | USD 0 | The current share valuation price of ABCL based on adjusted close was USD 3.6. The average price that ABCL shares were previous bought at was USD 3.29477. The current market price is 9.3% higher than average price they were purchased at. The value of the holding in ABCL has fallen by USD 23,146 compared to the previous valuation of Abcellera Biologics Inc |
| ABT - Abbott Laboratories | HOLD | 0 @ USD 130.03 | USD 0 | The current share valuation price of ABT based on adjusted close was USD 130.03. The average price that ABT shares were previous bought at was USD 124.109. The current market price is 4.8% higher than average price they were purchased at. The value of the holding in ABT has fallen by USD 62,000 compared to the previous valuation of Abbott Laboratories |
| ACAD - ACADIA Pharmaceuticals Inc | HOLD | 0 @ USD 24.01 | USD 0 | The current share valuation price of ACAD based on adjusted close was USD 24.01. The average price that ACAD shares were previous bought at was USD 17.44. The current market price is 37.7% higher than average price they were purchased at. The value of the holding in ACAD has fallen by USD 1,485 compared to the previous valuation of ACADIA Pharmaceuticals Inc |
| ACLX - Arcellx Inc | HOLD | 0 @ USD 90.34 | USD 0 | The current share valuation price of ACLX based on adjusted close was USD 90.34. The average price that ACLX shares were previous bought at was USD 63.8126. The current market price is 41.6% higher than average price they were purchased at. The value of the holding in ACLX has increased by USD 18,043 compared to the previous valuation of Arcellx Inc however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| ADPT - Adaptive Biotechnologies Corp | HOLD | 0 @ USD 13.71 | USD 0 | The current share valuation price of ADPT based on adjusted close was USD 13.71. The average price that ADPT shares were previous bought at was USD 6.33052. The current market price is 116.6% higher than average price they were purchased at. The value of the holding in ADPT has fallen by USD 72,258 compared to the previous valuation of Adaptive Biotechnologies Corp |
| ALKS - Alkermes Plc | HOLD | 0 @ USD 29.33 | USD 0 | The current share valuation price of ALKS based on adjusted close was USD 29.33. The average price that ALKS shares were previous bought at was USD 31.5876. The current market price is -7.1% lower than average price they were purchased at. The value of the holding in ALKS has increased by USD 57,450 compared to the previous valuation of Alkermes Plc however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| AMGN - Amgen Inc | HOLD | 0 @ USD 341.71 | USD 0 | The current share valuation price of AMGN based on adjusted close was USD 341.71. The average price that AMGN shares were previous bought at was USD 287.725. The current market price is 18.8% higher than average price they were purchased at. The value of the holding in AMGN has increased by USD 251,537 compared to the previous valuation of Amgen Inc however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| AMLX - Amylyx Pharmaceuticals Inc | HOLD | 0 @ USD 13.98 | USD 0 | The current share valuation price of AMLX based on adjusted close was USD 13.98. The average price that AMLX shares were previous bought at was USD 11.84. The current market price is 18.1% higher than average price they were purchased at. The value of the holding in AMLX has increased by USD 115,991 compared to the previous valuation of Amylyx Pharmaceuticals Inc however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| ANAB - AnaptysBio Inc | HOLD | 0 @ USD 34.77 | USD 0 | The current share valuation price of ANAB based on adjusted close was USD 34.77. The average price that ANAB shares were previous bought at was USD 22.9035. The current market price is 51.8% higher than average price they were purchased at. The value of the holding in ANAB has increased by USD 24,891 compared to the previous valuation of AnaptysBio Inc however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| ARCT - Arcturus Therapeutics Holdings Inc | HOLD | 0 @ USD 6.75999 | USD 0 | The current share valuation price of ARCT based on adjusted close was USD 6.75999. The average price that ARCT shares were previous bought at was USD 16.4363. The current market price is -58.9% lower than average price they were purchased at. The value of the holding in ARCT has fallen by USD 13,491 compared to the previous valuation of Arcturus Therapeutics Holdings Inc |
| ARVN - Arvinas Inc | HOLD | 0 @ USD 11.04 | USD 0 | The current share valuation price of ARVN based on adjusted close was USD 11.04. The average price that ARVN shares were previous bought at was USD 11.3332. The current market price is -2.6% lower than average price they were purchased at. The value of the holding in ARVN has increased by USD 40,305 compared to the previous valuation of Arvinas Inc however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| ASTH - Astrana Health Inc | HOLD | 0 @ USD 21.03 | USD 0 | The current share valuation price of ASTH based on adjusted close was USD 21.03. The average price that ASTH shares were previous bought at was USD 27.1156. The current market price is -22.4% lower than average price they were purchased at. The value of the holding in ASTH has fallen by USD 24,571 compared to the previous valuation of Astrana Health Inc |
| ATRC - AtriCure Inc | HOLD | 0 @ USD 33.12 | USD 0 | The current share valuation price of ATRC based on adjusted close was USD 33.12. The average price that ATRC shares were previous bought at was USD 33.1524. The current market price is -0.1% lower than average price they were purchased at. The value of the holding in ATRC has increased by USD 13,240 compared to the previous valuation of AtriCure Inc however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| AUPH - Aurinia Pharmaceuticals Inc | HOLD | 0 @ USD 15.49 | USD 0 | The current share valuation price of AUPH based on adjusted close was USD 15.49. The average price that AUPH shares were previous bought at was USD 8.80384. The current market price is 75.9% higher than average price they were purchased at. The value of the holding in AUPH has increased by USD 22,622 compared to the previous valuation of Aurinia Pharmaceuticals Inc however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| AXGN - Axogen Inc | HOLD | 0 @ USD 23.57 | USD 0 | The current share valuation price of AXGN based on adjusted close was USD 23.57. The average price that AXGN shares were previous bought at was USD 16.8496. The current market price is 39.9% higher than average price they were purchased at. The value of the holding in AXGN has increased by USD 1,071 compared to the previous valuation of Axogen Inc however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| AXSM - Axsome Therapeutics Inc | HOLD | 0 @ USD 145.56 | USD 0 | The current share valuation price of AXSM based on adjusted close was USD 145.56. The average price that AXSM shares were previous bought at was USD 105.595. The current market price is 37.8% higher than average price they were purchased at. The value of the holding in AXSM has increased by USD 271,100 compared to the previous valuation of Axsome Therapeutics Inc however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| BANB.SW - | HOLD | 0 @ CHF 63.0382 | CHF 0 | The current share valuation price of BANB.SW based on adjusted close was CHF 63.0382. The average price that BANB.SW shares were previous bought at was CHF 65.1273. The current market price is -3.2% lower than average price they were purchased at. The value of the holding in BANB.SW has fallen by CHF 37,644 (USD $47,394) compared to the previous valuation of |
| BAVA.CO - | HOLD | 0 @ DKK 28.5825 | DKK 0 | The current share valuation price of BAVA.CO based on adjusted close was DKK 28.5825. The average price that BAVA.CO shares were previous bought at was DKK 24.9137. The current market price is 14.7% higher than average price they were purchased at. The value of the holding in BAVA.CO has increased by DKK 110,637 (USD $17,211) compared to the previous valuation of however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| BCRX - BioCryst Pharmaceuticals Inc | HOLD | 0 @ USD 7.03 | USD 0 | The current share valuation price of BCRX based on adjusted close was USD 7.03. The average price that BCRX shares were previous bought at was USD 7.80196. The current market price is -9.9% lower than average price they were purchased at. The value of the holding in BCRX has fallen by USD 12,509 compared to the previous valuation of BioCryst Pharmaceuticals Inc |
| BEAM - Beam Therapeutics Inc | HOLD | 0 @ USD 22.02 | USD 0 | The current share valuation price of BEAM based on adjusted close was USD 22.02. The average price that BEAM shares were previous bought at was USD 17.8287. The current market price is 23.5% higher than average price they were purchased at. The value of the holding in BEAM has increased by USD 36,240 compared to the previous valuation of Beam Therapeutics Inc however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| BIIB - Biogen Inc | HOLD | 0 @ USD 164.68 | USD 0 | The current share valuation price of BIIB based on adjusted close was USD 164.68. The average price that BIIB shares were previous bought at was USD 128.1. The current market price is 28.6% higher than average price they were purchased at. The value of the holding in BIIB has fallen by USD 314,739 compared to the previous valuation of Biogen Inc |
| BIM.PA - BioMerieux | HOLD | 0 @ EUR 123.403 | EUR 0 | The current share valuation price of BIM.PA based on adjusted close was EUR 123.403. The average price that BIM.PA shares were previous bought at was EUR 119.434. The current market price is 3.3% higher than average price they were purchased at. The value of the holding in BIM.PA has fallen by EUR 90,806 (USD $105,474) compared to the previous valuation of BioMerieux |
| BIO - Bio-Rad Laboratories Inc | HOLD | 0 @ USD 304.06 | USD 0 | The current share valuation price of BIO based on adjusted close was USD 304.06. The average price that BIO shares were previous bought at was USD 280.042. The current market price is 8.6% higher than average price they were purchased at. The value of the holding in BIO has fallen by USD 234,404 compared to the previous valuation of Bio-Rad Laboratories Inc |
| BIO - Biotest Aktiengesellschaft | HOLD | 0 @ USD 304.06 | USD 0 | The current share valuation price of BIO based on adjusted close was USD 304.06. The average price that BIO shares were previous bought at was USD 280.042. The current market price is 8.6% higher than average price they were purchased at. The value of the holding in BIO has fallen by USD 234,404 compared to the previous valuation of Biotest Aktiengesellschaft |
| BIOA-B.ST - | HOLD | 0 @ SEK 30.2406 | SEK 0 | The current share valuation price of BIOA-B.ST based on adjusted close was SEK 30.2406. The average price that BIOA-B.ST shares were previous bought at was SEK 23.3486. The current market price is 29.5% higher than average price they were purchased at. The value of the holding in BIOA-B.ST has fallen by SEK 46,067 (USD $4,876) compared to the previous valuation of |
| BLFS - BioLife Solutions Inc | HOLD | 0 @ USD 24.01 | USD 0 | The current share valuation price of BLFS based on adjusted close was USD 24.01. The average price that BLFS shares were previous bought at was USD 26.74. The current market price is -10.2% lower than average price they were purchased at. The value of the holding in BLFS has fallen by USD 3,427 compared to the previous valuation of BioLife Solutions Inc |
| BMY - Bloomsbury Publishing Plc | HOLD | 0 @ USD 46.81 | USD 0 | The current share valuation price of BMY based on adjusted close was USD 46.81. The average price that BMY shares were previous bought at was USD 54.5268. The current market price is -14.2% lower than average price they were purchased at. The value of the holding in BMY has increased by USD 47,583 compared to the previous valuation of Bloomsbury Publishing Plc however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| BSX - Boston Scientific Corporation | HOLD | 0 @ USD 101.76 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 101.76. The average price that BSX shares were previous bought at was USD 96.7821. The current market price is 5.1% higher than average price they were purchased at. The value of the holding in BSX has fallen by USD 139,001 compared to the previous valuation of Boston Scientific Corporation |
| BSX - MULSTRXSSXIMETFP | HOLD | 0 @ USD 101.76 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 101.76. The average price that BSX shares were previous bought at was USD 96.7821. The current market price is 5.1% higher than average price they were purchased at. The value of the holding in BSX has fallen by USD 139,001 compared to the previous valuation of MULSTRXSSXIMETFP |
| CDNA - Caredx Inc | HOLD | 0 @ USD 15.51 | USD 0 | The current share valuation price of CDNA based on adjusted close was USD 15.51. The average price that CDNA shares were previous bought at was USD 19.5286. The current market price is -20.6% lower than average price they were purchased at. The value of the holding in CDNA has fallen by USD 26,638 compared to the previous valuation of Caredx Inc |
| CERT - Certara Inc | HOLD | 0 @ USD 8.17 | USD 0 | The current share valuation price of CERT based on adjusted close was USD 8.17. The average price that CERT shares were previous bought at was USD 10.5583. The current market price is -22.6% lower than average price they were purchased at. The value of the holding in CERT has fallen by USD 22,754 compared to the previous valuation of Certara Inc |
| CGON - CG Oncology, Inc. Common stock | HOLD | 0 @ USD 41.25 | USD 0 | The current share valuation price of CGON based on adjusted close was USD 41.25. The average price that CGON shares were previous bought at was USD 33.16. The current market price is 24.4% higher than average price they were purchased at. The value of the holding in CGON has increased by USD 17,657 compared to the previous valuation of CG Oncology, Inc. Common stock however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| CHEMM.CO - | HOLD | 0 @ DKK 117.25 | DKK 0 | The current share valuation price of CHEMM.CO based on adjusted close was DKK 117.25. The average price that CHEMM.CO shares were previous bought at was DKK 73.2155. The current market price is 60.1% higher than average price they were purchased at. The value of the holding in CHEMM.CO has fallen by DKK 39,900 (USD $6,207) compared to the previous valuation of |
| CPRX - Catalyst Pharmaceuticals Inc | HOLD | 0 @ USD 22.56 | USD 0 | The current share valuation price of CPRX based on adjusted close was USD 22.56. The average price that CPRX shares were previous bought at was USD 22.1952. The current market price is 1.6% higher than average price they were purchased at. The value of the holding in CPRX has fallen by USD 90,846 compared to the previous valuation of Catalyst Pharmaceuticals Inc |
| CRL - Creightons Plc | HOLD | 0 @ USD 162.74 | USD 0 | The current share valuation price of CRL based on adjusted close was USD 162.74. The average price that CRL shares were previous bought at was USD 161.828. The current market price is 0.6% higher than average price they were purchased at. The value of the holding in CRL has fallen by USD 301,802 compared to the previous valuation of Creightons Plc |
| CRVL - CorVel Corp | HOLD | 0 @ USD 72.7 | USD 0 | The current share valuation price of CRVL based on adjusted close was USD 72.7. The average price that CRVL shares were previous bought at was USD 112.167. The current market price is -35.2% lower than average price they were purchased at. The value of the holding in CRVL has fallen by USD 53,136 compared to the previous valuation of CorVel Corp |
| CSTL - Castle Biosciences Inc | HOLD | 0 @ USD 33.95 | USD 0 | The current share valuation price of CSTL based on adjusted close was USD 33.95. The average price that CSTL shares were previous bought at was USD 19.5501. The current market price is 73.7% higher than average price they were purchased at. The value of the holding in CSTL has increased by USD 17,611 compared to the previous valuation of Castle Biosciences Inc however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| DAWN - Day One Biopharmaceuticals Inc | HOLD | 0 @ USD 8.84 | USD 0 | The current share valuation price of DAWN based on adjusted close was USD 8.84. The average price that DAWN shares were previous bought at was USD 7.37. The current market price is 19.9% higher than average price they were purchased at. The value of the holding in DAWN has increased by USD 3,717 compared to the previous valuation of Day One Biopharmaceuticals Inc however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| DHR - Danaher Corporation | HOLD | 0 @ USD 220.44 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 220.44. The average price that DHR shares were previous bought at was USD 197.976. The current market price is 11.3% higher than average price they were purchased at. The value of the holding in DHR has fallen by USD 56,440 compared to the previous valuation of Danaher Corporation |
| DHR - Danaher Corporation | HOLD | 0 @ USD 220.44 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 220.44. The average price that DHR shares were previous bought at was USD 197.976. The current market price is 11.3% higher than average price they were purchased at. The value of the holding in DHR has fallen by USD 56,440 compared to the previous valuation of Danaher Corporation |
| DIA.MI - DiaSorin SpA | HOLD | 0 @ EUR 68.2658 | EUR 0 | The current share valuation price of DIA.MI based on adjusted close was EUR 68.2658. The average price that DIA.MI shares were previous bought at was EUR 51.5128. The current market price is 32.5% higher than average price they were purchased at. The value of the holding in DIA.MI has fallen by EUR 5,007 (USD $5,816) compared to the previous valuation of DiaSorin SpA |
| DVAX - Dynavax Technologies Corporation | HOLD | 0 @ USD 11.14 | USD 0 | The current share valuation price of DVAX based on adjusted close was USD 11.14. The average price that DVAX shares were previous bought at was USD 12.9918. The current market price is -14.3% lower than average price they were purchased at. The value of the holding in DVAX has increased by USD 11,536 compared to the previous valuation of Dynavax Technologies Corporation however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| DXCM - DexCom Inc | HOLD | 0 @ USD 58.49 | USD 0 | The current share valuation price of DXCM based on adjusted close was USD 58.49. The average price that DXCM shares were previous bought at was USD 79.7195. The current market price is -26.6% lower than average price they were purchased at. The value of the holding in DXCM has increased by USD 75,347 compared to the previous valuation of DexCom Inc however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| DYVOX.ST - | HOLD | 0 @ SEK 9.55717 | SEK 0 | The current share valuation price of DYVOX.ST based on adjusted close was SEK 9.55717. The average price that DYVOX.ST shares were previous bought at was SEK 6.01864. The current market price is 58.8% higher than average price they were purchased at. The value of the holding in DYVOX.ST has fallen by SEK 25,052 (USD $2,652) compared to the previous valuation of |
| EKTA-B.ST - | HOLD | 0 @ SEK 4.67662 | SEK 0 | The current share valuation price of EKTA-B.ST based on adjusted close was SEK 4.67662. The average price that EKTA-B.ST shares were previous bought at was SEK 5.55917. The current market price is -15.9% lower than average price they were purchased at. The value of the holding in EKTA-B.ST has fallen by SEK 46,965 (USD $4,971) compared to the previous valuation of |
| EMBC - Embecta Corp | HOLD | 0 @ USD 14.31 | USD 0 | The current share valuation price of EMBC based on adjusted close was USD 14.31. The average price that EMBC shares were previous bought at was USD 15.31. The current market price is -6.5% lower than average price they were purchased at. The value of the holding in EMBC has fallen by USD 16,837 compared to the previous valuation of Embecta Corp |
| EUZ.DE - Eckert & Ziegler SE | HOLD | 0 @ EUR 18.6612 | EUR 0 | The current share valuation price of EUZ.DE based on adjusted close was EUR 18.6612. The average price that EUZ.DE shares were previous bought at was EUR 20.0666. The current market price is -7.0% lower than average price they were purchased at. The value of the holding in EUZ.DE has fallen by EUR 12,241 (USD $14,218) compared to the previous valuation of Eckert & Ziegler SE |
| EVH - Evolent Health Inc | HOLD | 0 @ USD 3.87 | USD 0 | The current share valuation price of EVH based on adjusted close was USD 3.87. The average price that EVH shares were previous bought at was USD 10.5742. The current market price is -63.4% lower than average price they were purchased at. The value of the holding in EVH has fallen by USD 40,026 compared to the previous valuation of Evolent Health Inc |
| EVT.DE - Evotec SE | HOLD | 0 @ EUR 6.0472 | EUR 0 | The current share valuation price of EVT.DE based on adjusted close was EUR 6.0472. The average price that EVT.DE shares were previous bought at was EUR 6.57563. The current market price is -8.0% lower than average price they were purchased at. The value of the holding in EVT.DE has fallen by EUR 17,565 (USD $20,402) compared to the previous valuation of Evotec SE |
| EW - Edwards Lifesciences Corp | HOLD | 0 @ USD 84.74 | USD 0 | The current share valuation price of EW based on adjusted close was USD 84.74. The average price that EW shares were previous bought at was USD 73.5436. The current market price is 15.2% higher than average price they were purchased at. The value of the holding in EW has fallen by USD 305,636 compared to the previous valuation of Edwards Lifesciences Corp |
| EXAS - EXACT Sciences Corporation | HOLD | 0 @ USD 67.15 | USD 0 | The current share valuation price of EXAS based on adjusted close was USD 67.15. The average price that EXAS shares were previous bought at was USD 51.941. The current market price is 29.3% higher than average price they were purchased at. The value of the holding in EXAS has increased by USD 27,364 compared to the previous valuation of EXACT Sciences Corporation however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| EXEL - Exelixis Inc | HOLD | 0 @ USD 42.42 | USD 0 | The current share valuation price of EXEL based on adjusted close was USD 42.42. The average price that EXEL shares were previous bought at was USD 36.0106. The current market price is 17.8% higher than average price they were purchased at. The value of the holding in EXEL has increased by USD 253,704 compared to the previous valuation of Exelixis Inc however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| FTRE - Fortrea Holdings Inc. | HOLD | 0 @ USD 9.79 | USD 0 | The current share valuation price of FTRE based on adjusted close was USD 9.79. The average price that FTRE shares were previous bought at was USD 10.2008. The current market price is -4.0% lower than average price they were purchased at. The value of the holding in FTRE has fallen by USD 69,847 compared to the previous valuation of Fortrea Holdings Inc. |
| GH - Guardant Health Inc | HOLD | 0 @ USD 96.48 | USD 0 | The current share valuation price of GH based on adjusted close was USD 96.48. The average price that GH shares were previous bought at was USD 42.8441. The current market price is 125.2% higher than average price they were purchased at. The value of the holding in GH has increased by USD 317,079 compared to the previous valuation of Guardant Health Inc however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| GILD - Guild Esports Plc | HOLD | 0 @ USD 124.09 | USD 0 | The current share valuation price of GILD based on adjusted close was USD 124.09. The average price that GILD shares were previous bought at was USD 102.696. The current market price is 20.8% higher than average price they were purchased at. The value of the holding in GILD has fallen by USD 125,449 compared to the previous valuation of Guild Esports Plc |
| GLPG.AS - Galapagos NV | HOLD | 0 @ EUR 30.8739 | EUR 0 | The current share valuation price of GLPG.AS based on adjusted close was EUR 30.8739. The average price that GLPG.AS shares were previous bought at was EUR 28.0716. The current market price is 10.0% higher than average price they were purchased at. The value of the holding in GLPG.AS has fallen by EUR 38,171 (USD $44,337) compared to the previous valuation of Galapagos NV |
| GMAB.CO - | HOLD | 0 @ DKK 306.79 | DKK 0 | The current share valuation price of GMAB.CO based on adjusted close was DKK 306.79. The average price that GMAB.CO shares were previous bought at was DKK 214.002. The current market price is 43.4% higher than average price they were purchased at. The value of the holding in GMAB.CO has increased by DKK 195,514 (USD $30,415) compared to the previous valuation of however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| GSK.L - GlaxoSmithKline PLC | HOLD | 0 @ GBP 23.7111 | GBP 0 | The current share valuation price of GSK.L based on adjusted close was GBP 23.7111. The average price that GSK.L shares were previous bought at was GBP 18.3574. The current market price is 29.2% higher than average price they were purchased at. The value of the holding in GSK.L has increased by GBP 195,594 (USD $257,405) compared to the previous valuation of GlaxoSmithKline PLC however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| HALO - Halozyme Therapeutics Inc | HOLD | 0 @ USD 70.56 | USD 0 | The current share valuation price of HALO based on adjusted close was USD 70.56. The average price that HALO shares were previous bought at was USD 58.3208. The current market price is 21.0% higher than average price they were purchased at. The value of the holding in HALO has increased by USD 79,011 compared to the previous valuation of Halozyme Therapeutics Inc however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| HLUN-B.CO - | HOLD | 0 @ DKK 7.05362 | DKK 0 | The current share valuation price of HLUN-B.CO based on adjusted close was DKK 7.05362. The average price that HLUN-B.CO shares were previous bought at was DKK 5.84339. The current market price is 20.7% higher than average price they were purchased at. The value of the holding in HLUN-B.CO has fallen by DKK 8,196 (USD $1,275) compared to the previous valuation of |
| HOLX - Hologic Inc | HOLD | 0 @ USD 74.14 | USD 0 | The current share valuation price of HOLX based on adjusted close was USD 74.14. The average price that HOLX shares were previous bought at was USD 65.3166. The current market price is 13.5% higher than average price they were purchased at. The value of the holding in HOLX has fallen by USD 2,280 compared to the previous valuation of Hologic Inc |
| HRMY - Harmony Biosciences Holdings | HOLD | 0 @ USD 33.99 | USD 0 | The current share valuation price of HRMY based on adjusted close was USD 33.99. The average price that HRMY shares were previous bought at was USD 32.4203. The current market price is 4.8% higher than average price they were purchased at. The value of the holding in HRMY has fallen by USD 2,144 compared to the previous valuation of Harmony Biosciences Holdings |
| IART - Integra LifeSciences Holdings | HOLD | 0 @ USD 11.73 | USD 0 | The current share valuation price of IART based on adjusted close was USD 11.73. The average price that IART shares were previous bought at was USD 21.5655. The current market price is -45.6% lower than average price they were purchased at. The value of the holding in IART has fallen by USD 1,639 compared to the previous valuation of Integra LifeSciences Holdings |
| IBRX - Immunitybio Inc | HOLD | 0 @ USD 2.03 | USD 0 | The current share valuation price of IBRX based on adjusted close was USD 2.03. The average price that IBRX shares were previous bought at was USD 2.8497. The current market price is -28.8% lower than average price they were purchased at. The value of the holding in IBRX has fallen by USD 13,974 compared to the previous valuation of Immunitybio Inc |
| IDYA - Ideaya Biosciences Inc | HOLD | 0 @ USD 33.34 | USD 0 | The current share valuation price of IDYA based on adjusted close was USD 33.34. The average price that IDYA shares were previous bought at was USD 21.9973. The current market price is 51.6% higher than average price they were purchased at. The value of the holding in IDYA has increased by USD 126,258 compared to the previous valuation of Ideaya Biosciences Inc however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| ILMN - Illumina Inc | HOLD | 0 @ USD 120.08 | USD 0 | The current share valuation price of ILMN based on adjusted close was USD 120.08. The average price that ILMN shares were previous bought at was USD 92.7376. The current market price is 29.5% higher than average price they were purchased at. The value of the holding in ILMN has fallen by USD 99,568 compared to the previous valuation of Illumina Inc |
| IOVA - Iovance Biotherapeutics Inc | HOLD | 0 @ USD 2.42 | USD 0 | The current share valuation price of IOVA based on adjusted close was USD 2.42. The average price that IOVA shares were previous bought at was USD 2.4224. The current market price is -0.1% lower than average price they were purchased at. The value of the holding in IOVA has fallen by USD 16,890 compared to the previous valuation of Iovance Biotherapeutics Inc |
| IPN.PA - Ipsen SA | HOLD | 0 @ EUR 151.47 | EUR 0 | The current share valuation price of IPN.PA based on adjusted close was EUR 151.47. The average price that IPN.PA shares were previous bought at was EUR 115.732. The current market price is 30.9% higher than average price they were purchased at. The value of the holding in IPN.PA has fallen by EUR 59,961 (USD $69,647) compared to the previous valuation of Ipsen SA |
| IQV - IQVIA Holdings Inc | HOLD | 0 @ USD 216.12 | USD 0 | The current share valuation price of IQV based on adjusted close was USD 216.12. The average price that IQV shares were previous bought at was USD 158. The current market price is 36.8% higher than average price they were purchased at. The value of the holding in IQV has fallen by USD 417,386 compared to the previous valuation of IQVIA Holdings Inc |
| ISRG - Intuitive Surgical Inc | HOLD | 0 @ USD 546.71 | USD 0 | The current share valuation price of ISRG based on adjusted close was USD 546.71. The average price that ISRG shares were previous bought at was USD 526.895. The current market price is 3.8% higher than average price they were purchased at. The value of the holding in ISRG has fallen by USD 78,619 compared to the previous valuation of Intuitive Surgical Inc |
| JANX - Janux Therapeutics Inc | HOLD | 0 @ USD 28.72 | USD 0 | The current share valuation price of JANX based on adjusted close was USD 28.72. The average price that JANX shares were previous bought at was USD 25.3297. The current market price is 13.4% higher than average price they were purchased at. The value of the holding in JANX has fallen by USD 37,772 compared to the previous valuation of Janux Therapeutics Inc |
| JNJ - Johnson & Johnson | HOLD | 0 @ USD 199.58 | USD 0 | The current share valuation price of JNJ based on adjusted close was USD 199.58. The average price that JNJ shares were previous bought at was USD 155.455. The current market price is 28.4% higher than average price they were purchased at. The value of the holding in JNJ has increased by USD 346,509 compared to the previous valuation of Johnson & Johnson however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| KNSA - Kiniksa Pharmaceuticals Ltd | HOLD | 0 @ USD 41.4 | USD 0 | The current share valuation price of KNSA based on adjusted close was USD 41.4. The average price that KNSA shares were previous bought at was USD 37.01. The current market price is 11.9% higher than average price they were purchased at. The value of the holding in KNSA has increased by USD 54,917 compared to the previous valuation of Kiniksa Pharmaceuticals Ltd however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| KURA - Kura Oncology Inc | HOLD | 0 @ USD 10.85 | USD 0 | The current share valuation price of KURA based on adjusted close was USD 10.85. The average price that KURA shares were previous bought at was USD 8.825. The current market price is 22.9% higher than average price they were purchased at. The value of the holding in KURA has fallen by USD 33,863 compared to the previous valuation of Kura Oncology Inc |
| LAB - Standard Biotools Inc | HOLD | 0 @ USD 1.21 | USD 0 | The current share valuation price of LAB based on adjusted close was USD 1.21. The average price that LAB shares were previous bought at was USD 1.33. The current market price is -9.0% lower than average price they were purchased at. The value of the holding in LAB has fallen by USD 12,651 compared to the previous valuation of Standard Biotools Inc |
| LGND - Ligand Pharmaceuticals Incorporated | HOLD | 0 @ USD 201.35 | USD 0 | The current share valuation price of LGND based on adjusted close was USD 201.35. The average price that LGND shares were previous bought at was USD 112.221. The current market price is 79.4% higher than average price they were purchased at. The value of the holding in LGND has increased by USD 11,354 compared to the previous valuation of Ligand Pharmaceuticals Incorporated however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| LIVN - LivaNova PLC | HOLD | 0 @ USD 53.64 | USD 0 | The current share valuation price of LIVN based on adjusted close was USD 53.64. The average price that LIVN shares were previous bought at was USD 41.8947. The current market price is 28.0% higher than average price they were purchased at. The value of the holding in LIVN has fallen by USD 112,775 compared to the previous valuation of LivaNova PLC |
| LNTH - Lantheus Holdings Inc | HOLD | 0 @ USD 52.5 | USD 0 | The current share valuation price of LNTH based on adjusted close was USD 52.5. The average price that LNTH shares were previous bought at was USD 85.3876. The current market price is -38.5% lower than average price they were purchased at. The value of the holding in LNTH has fallen by USD 42,428 compared to the previous valuation of Lantheus Holdings Inc |
| LONN.SW - | HOLD | 0 @ CHF 678.021 | CHF 0 | The current share valuation price of LONN.SW based on adjusted close was CHF 678.021. The average price that LONN.SW shares were previous bought at was CHF 624.949. The current market price is 8.5% higher than average price they were purchased at. The value of the holding in LONN.SW has fallen by CHF 172,399 (USD $217,051) compared to the previous valuation of |
| MDT - Medtronic PLC | HOLD | 0 @ USD 96.28 | USD 0 | The current share valuation price of MDT based on adjusted close was USD 96.28. The average price that MDT shares were previous bought at was USD 86.0044. The current market price is 11.9% higher than average price they were purchased at. The value of the holding in MDT has increased by USD 69,258 compared to the previous valuation of Medtronic PLC however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| MEDP - Medpace Holdings Inc | HOLD | 0 @ USD 585.76 | USD 0 | The current share valuation price of MEDP based on adjusted close was USD 585.76. The average price that MEDP shares were previous bought at was USD 334.192. The current market price is 75.3% higher than average price they were purchased at. The value of the holding in MEDP has fallen by USD 125,630 compared to the previous valuation of Medpace Holdings Inc |
| MMS - LYXETFETUSITETFP | HOLD | 0 @ USD 78.36 | USD 0 | The current share valuation price of MMS based on adjusted close was USD 78.36. The average price that MMS shares were previous bought at was USD 73.448. The current market price is 6.7% higher than average price they were purchased at. The value of the holding in MMS has fallen by USD 98,725 compared to the previous valuation of LYXETFETUSITETFP |
| MRK - Marks Electrical Group PLC | HOLD | 0 @ USD 92.86 | USD 0 | The current share valuation price of MRK based on adjusted close was USD 92.86. The average price that MRK shares were previous bought at was USD 79.7125. The current market price is 16.5% higher than average price they were purchased at. The value of the holding in MRK has fallen by USD 10,953 compared to the previous valuation of Marks Electrical Group PLC |
| MRK - Merck & Company Inc | HOLD | 0 @ USD 92.86 | USD 0 | The current share valuation price of MRK based on adjusted close was USD 92.86. The average price that MRK shares were previous bought at was USD 79.7125. The current market price is 16.5% higher than average price they were purchased at. The value of the holding in MRK has fallen by USD 10,953 compared to the previous valuation of Merck & Company Inc |
| MRNA - Moderna Inc | HOLD | 0 @ USD 24.76 | USD 0 | The current share valuation price of MRNA based on adjusted close was USD 24.76. The average price that MRNA shares were previous bought at was USD 26.0014. The current market price is -4.8% lower than average price they were purchased at. The value of the holding in MRNA has fallen by USD 4,679 compared to the previous valuation of Moderna Inc |
| MRUS - Merus BV | HOLD | 0 @ USD 95.88 | USD 0 | The current share valuation price of MRUS based on adjusted close was USD 95.88. The average price that MRUS shares were previous bought at was USD 52.0801. The current market price is 84.1% higher than average price they were purchased at. The value of the holding in MRUS has fallen by USD 5,290 compared to the previous valuation of Merus BV |
| MRVI - Maravai Lifesciences Holdings Inc | HOLD | 0 @ USD 3.34 | USD 0 | The current share valuation price of MRVI based on adjusted close was USD 3.34. The average price that MRVI shares were previous bought at was USD 2.94723. The current market price is 13.3% higher than average price they were purchased at. The value of the holding in MRVI has fallen by USD 47,663 compared to the previous valuation of Maravai Lifesciences Holdings Inc |
| MYGN - Myriad Genetics Inc | HOLD | 0 @ USD 6.66 | USD 0 | The current share valuation price of MYGN based on adjusted close was USD 6.66. The average price that MYGN shares were previous bought at was USD 8.86565. The current market price is -24.9% lower than average price they were purchased at. The value of the holding in MYGN has fallen by USD 5,538 compared to the previous valuation of Myriad Genetics Inc |
| NBIX - Neurocrine Biosciences Inc | HOLD | 0 @ USD 143.56 | USD 0 | The current share valuation price of NBIX based on adjusted close was USD 143.56. The average price that NBIX shares were previous bought at was USD 124.213. The current market price is 15.6% higher than average price they were purchased at. The value of the holding in NBIX has fallen by USD 154,704 compared to the previous valuation of Neurocrine Biosciences Inc |
| NEOG - Neogen Corporation | HOLD | 0 @ USD 6.42 | USD 0 | The current share valuation price of NEOG based on adjusted close was USD 6.42. The average price that NEOG shares were previous bought at was USD 10.6516. The current market price is -39.7% lower than average price they were purchased at. The value of the holding in NEOG has increased by USD 7,861 compared to the previous valuation of Neogen Corporation however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| NEU.AX - | HOLD | 0 @ AUD 12.2955 | AUD 0 | The current share valuation price of NEU.AX based on adjusted close was AUD 12.2955. The average price that NEU.AX shares were previous bought at was AUD 6.49393. The current market price is 89.3% higher than average price they were purchased at. The value of the holding in NEU.AX has fallen by AUD 21,916 (USD $14,318) compared to the previous valuation of |
| NOVN.SW - | HOLD | 0 @ CHF 132.965 | CHF 0 | The current share valuation price of NOVN.SW based on adjusted close was CHF 132.965. The average price that NOVN.SW shares were previous bought at was CHF 105.855. The current market price is 25.6% higher than average price they were purchased at. The value of the holding in NOVN.SW has increased by CHF 169,366 (USD $213,232) compared to the previous valuation of however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| NTRA - Natera Inc | HOLD | 0 @ USD 206.04 | USD 0 | The current share valuation price of NTRA based on adjusted close was USD 206.04. The average price that NTRA shares were previous bought at was USD 159.203. The current market price is 29.4% higher than average price they were purchased at. The value of the holding in NTRA has increased by USD 158,157 compared to the previous valuation of Natera Inc however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| NUVB - Nuvation Bio Inc | HOLD | 0 @ USD 4.67 | USD 0 | The current share valuation price of NUVB based on adjusted close was USD 4.67. The average price that NUVB shares were previous bought at was USD 3.35. The current market price is 39.4% higher than average price they were purchased at. The value of the holding in NUVB has fallen by USD 56,326 compared to the previous valuation of Nuvation Bio Inc |
| NVAX - Novavax Inc | HOLD | 0 @ USD 6.8 | USD 0 | The current share valuation price of NVAX based on adjusted close was USD 6.8. The average price that NVAX shares were previous bought at was USD 6.52576. The current market price is 4.2% higher than average price they were purchased at. The value of the holding in NVAX has fallen by USD 31,252 compared to the previous valuation of Novavax Inc |
| NVAX - Hana Microelectronics Public Company Limited | HOLD | 0 @ USD 6.8 | USD 0 | The current share valuation price of NVAX based on adjusted close was USD 6.8. The average price that NVAX shares were previous bought at was USD 6.52576. The current market price is 4.2% higher than average price they were purchased at. The value of the holding in NVAX has fallen by USD 31,252 compared to the previous valuation of Hana Microelectronics Public Company Limited |
| NVCR - Novocure Ltd | HOLD | 0 @ USD 11.27 | USD 0 | The current share valuation price of NVCR based on adjusted close was USD 11.27. The average price that NVCR shares were previous bought at was USD 23.2352. The current market price is -51.5% lower than average price they were purchased at. The value of the holding in NVCR has fallen by USD 6,066 compared to the previous valuation of Novocure Ltd |
| ONT.L - Oxford Nanopore Technologies Ltd | HOLD | 0 @ GBP 1.68264 | GBP 0 | The current share valuation price of ONT.L based on adjusted close was GBP 1.68264. The average price that ONT.L shares were previous bought at was GBP 1.69938. The current market price is -1.0% lower than average price they were purchased at. The value of the holding in ONT.L has fallen by GBP 21,571 (USD $28,388) compared to the previous valuation of Oxford Nanopore Technologies Ltd |
| PACB - Pacific Biosciences of California | HOLD | 0 @ USD 1.57 | USD 0 | The current share valuation price of PACB based on adjusted close was USD 1.57. The average price that PACB shares were previous bought at was USD 1.30688. The current market price is 20.1% higher than average price they were purchased at. The value of the holding in PACB has fallen by USD 14,706 compared to the previous valuation of Pacific Biosciences of California |
| PFE - Pfizer Inc | HOLD | 0 @ USD 25.08 | USD 0 | The current share valuation price of PFE based on adjusted close was USD 25.08. The average price that PFE shares were previous bought at was USD 24.2467. The current market price is 3.4% higher than average price they were purchased at. The value of the holding in PFE has increased by USD 12,230 compared to the previous valuation of Pfizer Inc however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| PHARM.AS - Pharming Group NV | HOLD | 0 @ EUR 1.61444 | EUR 0 | The current share valuation price of PHARM.AS based on adjusted close was EUR 1.61444. The average price that PHARM.AS shares were previous bought at was EUR 0.824707. The current market price is 95.8% higher than average price they were purchased at. The value of the holding in PHARM.AS has fallen by EUR 60,854 (USD $70,684) compared to the previous valuation of Pharming Group NV |
| PHM.MC - Pharma Mar SA | HOLD | 0 @ EUR 87.7389 | EUR 0 | The current share valuation price of PHM.MC based on adjusted close was EUR 87.7389. The average price that PHM.MC shares were previous bought at was EUR 87.6333. The current market price is 0.1% higher than average price they were purchased at. The value of the holding in PHM.MC has fallen by EUR 1,878 (USD $2,181) compared to the previous valuation of Pharma Mar SA |
| PINC - Premier Inc | HOLD | 0 @ USD 28.19 | USD 0 | The current share valuation price of PINC based on adjusted close was USD 28.19. The average price that PINC shares were previous bought at was USD 26.81. The current market price is 5.1% higher than average price they were purchased at. USD 0 compared to the previous valuation of Premier Inc however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| PME.AX - | HOLD | 0 @ AUD 168.817 | AUD 0 | The current share valuation price of PME.AX based on adjusted close was AUD 168.817. The average price that PME.AX shares were previous bought at was AUD 163.975. The current market price is 3.0% higher than average price they were purchased at. The value of the holding in PME.AX has increased by AUD 401,200 (USD $262,104) compared to the previous valuation of however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| PODD - Insulet Corporation | HOLD | 0 @ USD 328.02 | USD 0 | The current share valuation price of PODD based on adjusted close was USD 328.02. The average price that PODD shares were previous bought at was USD 275.459. The current market price is 19.1% higher than average price they were purchased at. The value of the holding in PODD has fallen by USD 232,634 compared to the previous valuation of Insulet Corporation |
| PRAX - Praxis Precision Medicines Inc | HOLD | 0 @ USD 197.58 | USD 0 | The current share valuation price of PRAX based on adjusted close was USD 197.58. The average price that PRAX shares were previous bought at was USD 39.42. The current market price is 401.2% higher than average price they were purchased at. The value of the holding in PRAX has increased by USD 273,118 compared to the previous valuation of Praxis Precision Medicines Inc however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| PTCT - PTC Therapeutics Inc | HOLD | 0 @ USD 75.6 | USD 0 | The current share valuation price of PTCT based on adjusted close was USD 75.6. The average price that PTCT shares were previous bought at was USD 49.1674. The current market price is 53.8% higher than average price they were purchased at. The value of the holding in PTCT has increased by USD 28,575 compared to the previous valuation of PTC Therapeutics Inc however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| QDEL - Quidel Corporation | HOLD | 0 @ USD 21.1 | USD 0 | The current share valuation price of QDEL based on adjusted close was USD 21.1. The average price that QDEL shares were previous bought at was USD 29.6453. The current market price is -28.8% lower than average price they were purchased at. The value of the holding in QDEL has fallen by USD 19,494 compared to the previous valuation of Quidel Corporation |
| QIA.DE - QIAGEN NV | HOLD | 0 @ EUR 44.2464 | EUR 0 | The current share valuation price of QIA.DE based on adjusted close was EUR 44.2464. The average price that QIA.DE shares were previous bought at was EUR 40.6149. The current market price is 8.9% higher than average price they were purchased at. The value of the holding in QIA.DE has fallen by EUR 19,529 (USD $22,684) compared to the previous valuation of QIAGEN NV |
| RCUS - Arcus Biosciences Inc | HOLD | 0 @ USD 19.99 | USD 0 | The current share valuation price of RCUS based on adjusted close was USD 19.99. The average price that RCUS shares were previous bought at was USD 8.69153. The current market price is 130.0% higher than average price they were purchased at. The value of the holding in RCUS has fallen by USD 7,152 compared to the previous valuation of Arcus Biosciences Inc |
| RGEN - Repligen Corporation | HOLD | 0 @ USD 149 | USD 0 | The current share valuation price of RGEN based on adjusted close was USD 149. The average price that RGEN shares were previous bought at was USD 136.541. The current market price is 9.1% higher than average price they were purchased at. The value of the holding in RGEN has fallen by USD 213,523 compared to the previous valuation of Repligen Corporation |
| RGNX - Regenxbio Inc | HOLD | 0 @ USD 11.14 | USD 0 | The current share valuation price of RGNX based on adjusted close was USD 11.14. The average price that RGNX shares were previous bought at was USD 8.37881. The current market price is 33.0% higher than average price they were purchased at. The value of the holding in RGNX has fallen by USD 20,000 compared to the previous valuation of Regenxbio Inc |
| RLAY - Relay Therapeutics Inc | HOLD | 0 @ USD 6.62 | USD 0 | The current share valuation price of RLAY based on adjusted close was USD 6.62. The average price that RLAY shares were previous bought at was USD 3.79905. The current market price is 74.3% higher than average price they were purchased at. The value of the holding in RLAY has increased by USD 56,631 compared to the previous valuation of Relay Therapeutics Inc however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| RO.SW - | HOLD | 0 @ CHF 377.098 | CHF 0 | The current share valuation price of RO.SW based on adjusted close was CHF 377.098. The average price that RO.SW shares were previous bought at was CHF 367.716. The current market price is 2.6% higher than average price they were purchased at. The value of the holding in RO.SW has fallen by CHF 2,286 (USD $2,878) compared to the previous valuation of |
| ROG.SW - | HOLD | 0 @ CHF 361.008 | CHF 0 | The current share valuation price of ROG.SW based on adjusted close was CHF 361.008. The average price that ROG.SW shares were previous bought at was CHF 304.279. The current market price is 18.6% higher than average price they were purchased at. The value of the holding in ROG.SW has increased by CHF 17,688 (USD $22,269) compared to the previous valuation of however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| RVTY - Revvity Inc. | HOLD | 0 @ USD 91.06 | USD 0 | The current share valuation price of RVTY based on adjusted close was USD 91.06. The average price that RVTY shares were previous bought at was USD 87.5022. The current market price is 4.1% higher than average price they were purchased at. The value of the holding in RVTY has fallen by USD 237,808 compared to the previous valuation of Revvity Inc. |
| RXRX - Recursion Pharmaceuticals Inc | HOLD | 0 @ USD 4.12 | USD 0 | The current share valuation price of RXRX based on adjusted close was USD 4.12. The average price that RXRX shares were previous bought at was USD 5.16079. The current market price is -20.2% lower than average price they were purchased at. The value of the holding in RXRX has fallen by USD 9,601 compared to the previous valuation of Recursion Pharmaceuticals Inc |
| RYTM - Rhythm Pharmaceuticals Inc | HOLD | 0 @ USD 100.69 | USD 0 | The current share valuation price of RYTM based on adjusted close was USD 100.69. The average price that RYTM shares were previous bought at was USD 64.092. The current market price is 57.1% higher than average price they were purchased at. The value of the holding in RYTM has increased by USD 90,308 compared to the previous valuation of Rhythm Pharmaceuticals Inc however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| SDGR - Schrodinger Inc | HOLD | 0 @ USD 17.46 | USD 0 | The current share valuation price of SDGR based on adjusted close was USD 17.46. The average price that SDGR shares were previous bought at was USD 23.4925. The current market price is -25.7% lower than average price they were purchased at. The value of the holding in SDGR has fallen by USD 12,682 compared to the previous valuation of Schrodinger Inc |
| SECT-B.ST - | HOLD | 0 @ SEK 30.3885 | SEK 0 | The current share valuation price of SECT-B.ST based on adjusted close was SEK 30.3885. The average price that SECT-B.ST shares were previous bought at was SEK 27.1554. The current market price is 11.9% higher than average price they were purchased at. The value of the holding in SECT-B.ST has fallen by SEK 52,910 (USD $5,600) compared to the previous valuation of |
| SFZN.SW - | HOLD | 0 @ CHF 89.2464 | CHF 0 | The current share valuation price of SFZN.SW based on adjusted close was CHF 89.2464. The average price that SFZN.SW shares were previous bought at was CHF 124.687. The current market price is -28.4% lower than average price they were purchased at. The value of the holding in SFZN.SW has fallen by CHF 252,168 (USD $317,480) compared to the previous valuation of |
| SLP - Sylvania Platinum Limited | HOLD | 0 @ USD 16.98 | USD 0 | The current share valuation price of SLP based on adjusted close was USD 16.98. The average price that SLP shares were previous bought at was USD 26.7306. The current market price is -36.5% lower than average price they were purchased at. The value of the holding in SLP has fallen by USD 6,065 compared to the previous valuation of Sylvania Platinum Limited |
| SRPT - Sarepta Therapeutics Inc | HOLD | 0 @ USD 17.54 | USD 0 | The current share valuation price of SRPT based on adjusted close was USD 17.54. The average price that SRPT shares were previous bought at was USD 57.6553. The current market price is -69.6% lower than average price they were purchased at. The value of the holding in SRPT has fallen by USD 149,920 compared to the previous valuation of Sarepta Therapeutics Inc |
| SRT3.DE - Sartorius AG | HOLD | 0 @ EUR 264.666 | EUR 0 | The current share valuation price of SRT3.DE based on adjusted close was EUR 264.666. The average price that SRT3.DE shares were previous bought at was EUR 226.06. The current market price is 17.1% higher than average price they were purchased at. The value of the holding in SRT3.DE has fallen by EUR 84,288 (USD $97,903) compared to the previous valuation of Sartorius AG |
| STOK - Stoke Therapeutics Inc | HOLD | 0 @ USD 26.95 | USD 0 | The current share valuation price of STOK based on adjusted close was USD 26.95. The average price that STOK shares were previous bought at was USD 11.6276. The current market price is 131.8% higher than average price they were purchased at. The value of the holding in STOK has increased by USD 28,842 compared to the previous valuation of Stoke Therapeutics Inc however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| SUPN - Supernus Pharmaceuticals Inc | HOLD | 0 @ USD 45.09 | USD 0 | The current share valuation price of SUPN based on adjusted close was USD 45.09. The average price that SUPN shares were previous bought at was USD 34.9586. The current market price is 29.0% higher than average price they were purchased at. The value of the holding in SUPN has increased by USD 6,108 compared to the previous valuation of Supernus Pharmaceuticals Inc however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| SXS.L - Spectris PLC | HOLD | 0 @ GBP 54.1818 | GBP 0 | The current share valuation price of SXS.L based on adjusted close was GBP 54.1818. The average price that SXS.L shares were previous bought at was GBP 55.4271. The current market price is -2.2% lower than average price they were purchased at. The value of the holding in SXS.L has increased by GBP 17,652 (USD $23,230) compared to the previous valuation of Spectris PLC however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| TECH - Bio-Techne Corp | HOLD | 0 @ USD 58.61 | USD 0 | The current share valuation price of TECH based on adjusted close was USD 58.61. The average price that TECH shares were previous bought at was USD 58.2868. The current market price is 0.6% higher than average price they were purchased at. The value of the holding in TECH has fallen by USD 146,210 compared to the previous valuation of Bio-Techne Corp |
| TECN.SW - | HOLD | 0 @ CHF 174.219 | CHF 0 | The current share valuation price of TECN.SW based on adjusted close was CHF 174.219. The average price that TECN.SW shares were previous bought at was CHF 202.814. The current market price is -14.1% lower than average price they were purchased at. The value of the holding in TECN.SW has fallen by CHF 34,948 (USD $44,000) compared to the previous valuation of |
| TGTX - TG Therapeutics Inc | HOLD | 0 @ USD 30.69 | USD 0 | The current share valuation price of TGTX based on adjusted close was USD 30.69. The average price that TGTX shares were previous bought at was USD 34.3438. The current market price is -10.6% lower than average price they were purchased at. The value of the holding in TGTX has fallen by USD 53,461 compared to the previous valuation of TG Therapeutics Inc |
| TMO - Time Out Group plc | HOLD | 0 @ USD 567.16 | USD 0 | The current share valuation price of TMO based on adjusted close was USD 567.16. The average price that TMO shares were previous bought at was USD 407.896. The current market price is 39.0% higher than average price they were purchased at. The value of the holding in TMO has fallen by USD 413,848 compared to the previous valuation of Time Out Group plc |
| TNDM - Tandem Diabetes Care Inc | HOLD | 0 @ USD 18.34 | USD 0 | The current share valuation price of TNDM based on adjusted close was USD 18.34. The average price that TNDM shares were previous bought at was USD 22.0991. The current market price is -17.0% lower than average price they were purchased at. The value of the holding in TNDM has fallen by USD 21,484 compared to the previous valuation of Tandem Diabetes Care Inc |
| TWST - Twist Bioscience Corp | HOLD | 0 @ USD 26.46 | USD 0 | The current share valuation price of TWST based on adjusted close was USD 26.46. The average price that TWST shares were previous bought at was USD 42.9063. The current market price is -38.3% lower than average price they were purchased at. The value of the holding in TWST has fallen by USD 27,033 compared to the previous valuation of Twist Bioscience Corp |
| TXG - 10X Genomics Inc | HOLD | 0 @ USD 15.7 | USD 0 | The current share valuation price of TXG based on adjusted close was USD 15.7. The average price that TXG shares were previous bought at was USD 11.9745. The current market price is 31.1% higher than average price they were purchased at. The value of the holding in TXG has fallen by USD 25,352 compared to the previous valuation of 10X Genomics Inc |
| TXG - Terex Corporation | HOLD | 0 @ USD 15.7 | USD 0 | The current share valuation price of TXG based on adjusted close was USD 15.7. The average price that TXG shares were previous bought at was USD 11.9745. The current market price is 31.1% higher than average price they were purchased at. The value of the holding in TXG has fallen by USD 25,352 compared to the previous valuation of Terex Corporation |
| UCB.BR - UCB SA | HOLD | 0 @ EUR 265.13 | EUR 0 | The current share valuation price of UCB.BR based on adjusted close was EUR 265.13. The average price that UCB.BR shares were previous bought at was EUR 188.363. The current market price is 40.8% higher than average price they were purchased at. The value of the holding in UCB.BR has increased by EUR 128,726 (USD $149,520) compared to the previous valuation of UCB SA however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| VCYT - Veracyte Inc | HOLD | 0 @ USD 39.28 | USD 0 | The current share valuation price of VCYT based on adjusted close was USD 39.28. The average price that VCYT shares were previous bought at was USD 31.3293. The current market price is 25.4% higher than average price they were purchased at. The value of the holding in VCYT has fallen by USD 6,277 compared to the previous valuation of Veracyte Inc |
| VIR - Vir Biotechnology Inc | HOLD | 0 @ USD 5.49 | USD 0 | The current share valuation price of VIR based on adjusted close was USD 5.49. The average price that VIR shares were previous bought at was USD 8.03707. The current market price is -31.7% lower than average price they were purchased at. The value of the holding in VIR has fallen by USD 17,326 compared to the previous valuation of Vir Biotechnology Inc |
| VIR - Vidrala S.A | HOLD | 0 @ USD 5.49 | USD 0 | The current share valuation price of VIR based on adjusted close was USD 5.49. The average price that VIR shares were previous bought at was USD 8.03707. The current market price is -31.7% lower than average price they were purchased at. The value of the holding in VIR has fallen by USD 17,326 compared to the previous valuation of Vidrala S.A |
| VLA.PA - Valneva SE | HOLD | 0 @ EUR 4.4374 | EUR 0 | The current share valuation price of VLA.PA based on adjusted close was EUR 4.4374. The average price that VLA.PA shares were previous bought at was EUR 2.86092. The current market price is 55.1% higher than average price they were purchased at. The value of the holding in VLA.PA has fallen by EUR 8,698 (USD $10,103) compared to the previous valuation of Valneva SE |
| VNDA - Vanda Pharmaceuticals Inc | HOLD | 0 @ USD 4.4 | USD 0 | The current share valuation price of VNDA based on adjusted close was USD 4.4. The average price that VNDA shares were previous bought at was USD 4.49047. The current market price is -2.0% lower than average price they were purchased at. The value of the holding in VNDA has increased by USD 3,423 compared to the previous valuation of Vanda Pharmaceuticals Inc however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| VRDN - Viridian Therapeutics Inc | HOLD | 0 @ USD 29 | USD 0 | The current share valuation price of VRDN based on adjusted close was USD 29. The average price that VRDN shares were previous bought at was USD 19.65. The current market price is 47.6% higher than average price they were purchased at. The value of the holding in VRDN has increased by USD 22,750 compared to the previous valuation of Viridian Therapeutics Inc however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| XVIVO.ST - | HOLD | 0 @ SEK 17.2758 | SEK 0 | The current share valuation price of XVIVO.ST based on adjusted close was SEK 17.2758. The average price that XVIVO.ST shares were previous bought at was SEK 42.7002. The current market price is -59.5% lower than average price they were purchased at. The value of the holding in XVIVO.ST has fallen by SEK 3,033 (USD $321) compared to the previous valuation of |
| ZYME - Zymeworks Inc. Common Stock | HOLD | 0 @ USD 23.9 | USD 0 | The current share valuation price of ZYME based on adjusted close was USD 23.9. The average price that ZYME shares were previous bought at was USD 14.3. The current market price is 67.1% higher than average price they were purchased at. The value of the holding in ZYME has increased by USD 334,738 compared to the previous valuation of Zymeworks Inc. Common Stock however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| CTKB - Cytek Biosciences Inc | SELL | -1,504 @ USD 5.29 | USD -7,956 | The ETF sold 1504 shares of CTKB on 2025-11-17. The shares were previously bought for an average price of USD 5.75945. The Cytek Biosciences Inc shares were sold for -8.2% lower than average price of previous purchases. This resulted in an overall loss of USD 706 The average price that the ETF previously sold CTKB share for is USD 4.44769 so the ETF has sold 1504 shares on 2025-11-17 at a higher price than the previous selling average. |